false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Didactics
Cancer Immunotherapy
Cancer Immunotherapy
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video discusses various forms of T-cell transfer therapy, specifically focusing on CAR-T and TILT therapies. CAR-T (chimeric antigen receptor T-cell) therapy involves genetically engineering T-cells to recognize and bind to specific antigens on cancer cells. This therapy has shown promise in hematologic malignancies but is still being researched for solid tumors. The video explains the complex process of collecting, engineering, and reinfusing the patient's own T-cells. It also mentions the potential side effects of cytokine release syndrome and neurotoxic syndrome. TILT (tumor infiltrating lymphocyte) therapy involves harvesting and infusing tumor-specific lymphocytes to stimulate an immune response. The video discusses the ongoing clinical trials for TILT therapy in cervical cancer and the promising results seen so far. Additionally, a new trial called T-Vigil is mentioned, which involves engineering autologous vaccines from tumor specimens. The video highlights the challenges of these therapies, such as complexity, cost, and finding the right antigen for specific cancers. Overall, adoptive T-cell therapies show potential in treating various cancers but still require further research and refinement.
Asset Subtitle
Linda Van Le
March 2023
Keywords
T-cell transfer therapy
CAR-T therapy
TILT therapy
cytokine release syndrome
neurotoxic syndrome
Contact
education@igcs.org
for assistance.
×